Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Contact Supplier

Jai Radhe Sales is your partner for all your sourcing needs.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 KDMF, $ API Reference Price

1 KDMF
$ API Reference Price

DEVELOPMENTS

23 Drugs in Development

23 Drugs in Development

DIGITAL CONTENT

19 NEWS #PharmaBuzz

media
19 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1903008-80-9, Yh-25448, Gns-1480, Yh25448, Gns1480, Jnj-73841937-aaa

Molecular Formula

C₃₀H₃₄N₈O₃

Molecular Weight

554.6 g/mol

InChI Key

RRMJMHOQSALEJJ-UHFFFAOYSA-N

FDA UNII

4A2Y23XK11

Lazertinib is an orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, including the resistance mutation T790M, exon 19 deletions (Del19), and the L858R mutation, with potential antineoplastic activity. Upon administration, lazertinib specifically and irreversibly binds to and inhibits selective EGFR mutants, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Lazertinib may inhibit programmed cell death-1 ligand 1 (PD-L1) and inflammatory cytokines in specific cancer cells harboring certain EGFR mutations. Compared to some other EGFR inhibitors, lazertinib may have therapeutic benefits in tumors with T790M- or L858R-mediated drug resistance. In addition, lazertinib penetrates the blood-brain barrier (BBB). This agent shows minimal activity against wild-type EGFR (wtEGFR), and does not cause dose-limiting toxicities, which occur during the use of non-selective EGFR inhibitors and inhibit wtEGFR. EGFR, a receptor tyrosine kinase (RTK) mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.

1 2D Structure

Lazertinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide

2.1.2 InChI

InChI=1S/C30H34N8O3/c1-5-28(39)32-23-17-24(26(40-4)18-25(23)37-13-15-41-16-14-37)33-30-31-12-11-27(34-30)38-20-22(19-36(2)3)29(35-38)21-9-7-6-8-10-21/h5-12,17-18,20H,1,13-16,19H2,2-4H3,(H,32,39)(H,31,33,34)

2.1.3 InChI Key

RRMJMHOQSALEJJ-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CN(C)CC1=CN(N=C1C2=CC=CC=C2)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N5CCOCC5)OC

2.2 Other Identifiers

2.2.1 UNII

4A2Y23XK11

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-propenamide, N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)-

2. Leclaza

3. N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)acrylamide

2.3.2 Depositor-Supplied Synonyms

1. 1903008-80-9

2. Yh-25448

3. Gns-1480

4. Yh25448

5. Gns1480

6. Jnj-73841937-aaa

7. Lazertinib [usan]

8. C-18112003-g

9. N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide

10. 4a2y23xk11

11. N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamide

12. 2-propenamide, N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)-

13. Leclaza

14. Lazertinib [inn]

15. Lazertinib [inn]

16. Lazertinib (yh25448)

17. Lazertinib [who-dd]

18. Unii-4a2y23xk11

19. Chembl4558324

20. Schembl17670400

21. Gtpl10136

22. Bcp30440

23. Ex-a1912

24. Bdbm50555575

25. S8724

26. Who 10587

27. Akos037515597

28. Ccg-270023

29. Lazertinib (yh25448,gns-1480)

30. Yh-25448;gns-1480

31. Ac-36243

32. Bs-15742

33. Compound 73 [wo2016060443a2]

34. Hy-109061

35. Cs-0032992

36. A16827

37. A903188

38. Yh-25448; Yh 25448; Yh25448; Gns-1480; Gns 1480; Gns1480

39. N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)acrylamide

40. N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide

2.4 Create Date

2016-08-06

3 Chemical and Physical Properties

Molecular Formula	C₃₀H₃₄N₈O₃
Molecular Weight	554.6 g/mol
XLogP3	3.4
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	9
Rotatable Bond Count	10
Exact Mass	554.27538698 g/mol
Monoisotopic Mass	554.27538698 g/mol
Topological Polar Surface Area	110 Å²
Heavy Atom Count	41
Formal Charge	0
Complexity	837
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)

KDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

[{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1624645800,"product":"(N.C.V) REF.STD. LAZERTINIB (JNJ-73841937-ZCY)R605024 2-PROPENAMIDE,N-[5-[[4-[4-(DIMETHYLAMINO)METHYL]-3-PHENYL-1H-PYRAZ","address":"30 FORJETT STREETPOST BOX NO 9301","city":"MUMBAI, MAHARASHTRA.","supplier":"JOHNSON & JOHNSON","supplierCountry":"BELGIUM","foreign_port":"BRUSSELS","customer":"JOHNSON & JOHNSON","customerCountry":"INDIA","quantity":"0.04","actualQuantity":"40","unit":"GMS","unitRateFc":"286","totalValueFC":"13999.5","currency":"EUR","unitRateINR":"25740","date":"26-Jun-2021","totalValueINR":"1029600","totalValueInUsd":"13999.5","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"4466841","productDescription":"API","marketType":"REGULATED MARKET","country":"BELGIUM","selfForZScoreResived":"Pharma Grade","supplierPort":"BRUSSELS","supplierAddress":"","customerAddress":"30 FORJETT STREETPOST BOX NO 9301"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1630434600,"product":"(N.C.V) LAZERTINIB (JNJ-73841937-ZCY)R605024.REF.STD. 2-PROPENAMIDE,N[5-[[4-[4-[(DIMETHYLAMINO)METHYL]-3-PHENYL-1H-PYRAZ","address":"30 FORJETT STREETPOST BOX NO 9301","city":"MUMBAI, MAHARASHTRA.","supplier":"JOHNSON & JOHNSON","supplierCountry":"BELGIUM","foreign_port":"BRUSSELS","customer":"JOHNSON & JOHNSON","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"2.5","unit":"GMS","unitRateFc":"286","totalValueFC":"859.3","currency":"EUR","unitRateINR":"25282.4","date":"01-Sep-2021","totalValueINR":"63206","totalValueInUsd":"859.3","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"5268720","productDescription":"API","marketType":"REGULATED MARKET","country":"BELGIUM","selfForZScoreResived":"Pharma Grade","supplierPort":"BRUSSELS","supplierAddress":"","customerAddress":"30 FORJETT STREETPOST BOX NO 9301"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1661538600,"product":"(N.C.V) SELECTIVITY BATCH OF JNJ-73841937-AAA,LAZERTINIB 2-PROPNAMIDE ,N-5[5-[[4-[4-[(DIMETHYLLAMINO)METHYL]-3-PHENYL-1H","address":"L.B.S. MARG,,MULUND-WEST","city":"MUMBAI,MAHARASHTRA","supplier":"JOHNSON & JOHNSON","supplierCountry":"BELGIUM","foreign_port":"NA","customer":"JOHNSON & JOHNSON","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"1","unit":"GMS","unitRateFc":"1327","totalValueFC":"1376.7","currency":"EUR","unitRateINR":"109543.9","date":"27-Aug-2022","totalValueINR":"109543.85","totalValueInUsd":"1376.7","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"2188581","productDescription":"API","marketType":"REGULATED MARKET","country":"BELGIUM","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"L.B.S. MARG,,MULUND-WEST"}]

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country	Total Quantity (KGS)	Average Price (USD/KGS)	Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

ABOUT THIS PAGE

Find Lazertinib manufacturers, exporters & distributors on PharmaCompass

Lazertinib

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 KDMF

$ API Reference Price

DEVELOPMENTS

23 Drugs in Development

DIGITAL CONTENT

19 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 317,623

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

23DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

What are you looking for?